Top Markets
Coin of the day
BioAge Labs Inc. BioAge Labs Inc.

BioAge Labs Inc.

BIOA
Pozycja w akcjach #15401
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops... BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Cena akcji
$9.50
Kapitalizacja rynkowa
$357.67M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
92.70%
Kraj
US
Handel BioAge Labs Inc. (BIOA)

Kategoria

Historia ceny akcji dla BioAge Labs Inc. (BIOA)
Najwyższa cena zamknięcia: $9.50 dnia 2026-09-01

Najniższa cena zamknięcia: $20.04 dnia 2024-09-01
Historia cen akcji firmy BioAge Labs Inc. od 2024 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2026 (TTM) 19.87%
2025 48.86%
2024 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$548.98 40.40%
US
$1.03K 44.32%
NL
$121.37 -11.93%
AU
$144.39 499.38%
US
$748.60 4.92%
CH